Comparison of clinical outcomes of cabozantinib plus nivolumab and lenvatinib plus pembrolizumab in patients with metastatic renal cell carcinoma.

IF 1.9 4区医学 Q3 UROLOGY & NEPHROLOGY

International Urology and Nephrology Pub Date : 2026-05-07 DOI:10.1007/s11255-026-05174-5

Kazutaka Nakamura, Kazuhiko Yoshida, Yuki Kobari, Yuki Nemoto, Hiroki Ishihara, Hironori Fukuda, Junpei Iizuka, Hiroaki Shimmura, Hiroshi Kobayashi, Yasunobu Hashimoto, Tsunenori Kondo, Toshio Takagi

{"title":"Comparison of clinical outcomes of cabozantinib plus nivolumab and lenvatinib plus pembrolizumab in patients with metastatic renal cell carcinoma.","authors":"Kazutaka Nakamura, Kazuhiko Yoshida, Yuki Kobari, Yuki Nemoto, Hiroki Ishihara, Hironori Fukuda, Junpei Iizuka, Hiroaki Shimmura, Hiroshi Kobayashi, Yasunobu Hashimoto, Tsunenori Kondo, Toshio Takagi","doi":"10.1007/s11255-026-05174-5","DOIUrl":null,"url":null,"abstract":"Purpose: This study aimed to evaluate the treatment outcomes and safety of cabozantinib plus nivolumab (C + N) and lenvatinib plus pembrolizumab (L + P) for patients with metastatic renal cell carcinoma (mRCC).Methods: This multicenter retrospective analysis included 92 patients with mRCC treated with either C + N or L + P as first-line therapy between April 2018 and August 2024. Progression-free survival (PFS), overall survival (OS), objective response rate (ORR), disease control rate (DCR), and treatment-related adverse events (TRAEs) were compared. Multivariable analysis was performed to identify independent prognostic factors for PFS.Results: Fifty-three patients received C + N and 39 received L + P. PFS (24.1 months vs. not reached, P = 0.725) and OS (46.7 months vs. not reached, P = 0.912) were not significantly different between the C + N and L + P groups. Over a median follow-up duration of 13.9 months, 31 patients experienced disease progression and 12 died. ORR was higher in the C + N group than in the L + P group (79% vs. 49%, P = 0.002), whereas DCR (100% vs. 95%, P = 0.096) and grade ≥ 3 TRAEs (47% vs. 36%, P = 0.280) were comparable. In the multivariable analysis, the treatment regimen (C + N as a reference) was not significantly associated with PFS (hazard ratio: 0.76, P = 0.476). Favorable/intermediate International mRCC Database Consortium risk was identified as an independent prognostic factor for PFS.Conclusion: Treatment with C + N and L + P resulted in comparable PFS, OS, and safety profiles in patients with mRCC. Both regimens can be used to treat mRCC based on individual characteristics.","PeriodicalId":14454,"journal":{"name":"International Urology and Nephrology","volume":" ","pages":""},"PeriodicalIF":1.9000,"publicationDate":"2026-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Urology and Nephrology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11255-026-05174-5","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: This study aimed to evaluate the treatment outcomes and safety of cabozantinib plus nivolumab (C + N) and lenvatinib plus pembrolizumab (L + P) for patients with metastatic renal cell carcinoma (mRCC).

Methods: This multicenter retrospective analysis included 92 patients with mRCC treated with either C + N or L + P as first-line therapy between April 2018 and August 2024. Progression-free survival (PFS), overall survival (OS), objective response rate (ORR), disease control rate (DCR), and treatment-related adverse events (TRAEs) were compared. Multivariable analysis was performed to identify independent prognostic factors for PFS.

Results: Fifty-three patients received C + N and 39 received L + P. PFS (24.1 months vs. not reached, P = 0.725) and OS (46.7 months vs. not reached, P = 0.912) were not significantly different between the C + N and L + P groups. Over a median follow-up duration of 13.9 months, 31 patients experienced disease progression and 12 died. ORR was higher in the C + N group than in the L + P group (79% vs. 49%, P = 0.002), whereas DCR (100% vs. 95%, P = 0.096) and grade ≥ 3 TRAEs (47% vs. 36%, P = 0.280) were comparable. In the multivariable analysis, the treatment regimen (C + N as a reference) was not significantly associated with PFS (hazard ratio: 0.76, P = 0.476). Favorable/intermediate International mRCC Database Consortium risk was identified as an independent prognostic factor for PFS.

Conclusion: Treatment with C + N and L + P resulted in comparable PFS, OS, and safety profiles in patients with mRCC. Both regimens can be used to treat mRCC based on individual characteristics.

查看原文本刊更多论文

卡博赞替尼联合纳武单抗与lenvatinib联合派姆单抗治疗转移性肾细胞癌的临床疗效比较

目的：本研究旨在评价cabozantinib + nivolumab （C + N）和lenvatinib + pembrolizumab （L + P）对转移性肾细胞癌（mRCC）患者的治疗效果和安全性。方法：这项多中心回顾性分析纳入了2018年4月至2024年8月期间92例接受C + N或L + P作为一线治疗的mRCC患者。比较无进展生存期（PFS）、总生存期（OS）、客观缓解率（ORR）、疾病控制率（DCR）和治疗相关不良事件（TRAEs）。进行多变量分析以确定PFS的独立预后因素。结果：C + N 53例，L + P 39例。PFS（24.1个月vs.未达到，P = 0.725）和OS（46.7个月vs.未达到，P = 0.912）在C + N组和L + P组之间无显著差异。在13.9个月的中位随访期间，31名患者出现疾病进展，12名患者死亡。C + N组的ORR高于L + P组（79% vs. 49%, P = 0.002），而DCR （100% vs. 95%, P = 0.096）和≥3级TRAEs （47% vs. 36%, P = 0.280）具有可比性。在多变量分析中，治疗方案（以C + N为参照）与PFS无显著相关（风险比：0.76,P = 0.476）。有利/中级国际mRCC数据库联盟风险被确定为PFS的独立预后因素。结论：在mRCC患者中，C + N和L + P治疗的PFS、OS和安全性相当。两种方案均可用于治疗基于个体特征的mRCC。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Urology and Nephrology 医学-泌尿学与肾脏学

CiteScore

3.40

自引率

5.00%

发文量

329

审稿时长

1.7 months

期刊介绍： International Urology and Nephrology publishes original papers on a broad range of topics in urology, nephrology and andrology. The journal integrates papers originating from clinical practice.